Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Palovarotene (Ro 3300074) 是核视网膜酸受体γ 的激动剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 279 | 现货 | ||
5 mg | ¥ 659 | 现货 | ||
10 mg | ¥ 987 | 现货 | ||
25 mg | ¥ 1,970 | 现货 | ||
50 mg | ¥ 2,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 778 | 现货 |
产品描述 | Palovarotene (Ro 3300074) is an agonist of nuclear retinoic acid receptor γ (RAR-γ). |
体内活性 | Palovarotene inhibits post-traumatic chondrogenesis and osteogenesis and mitigated trauma-induced ectopic bone formation. Palovarotene inhibits subcutaneous and intramuscular heterotopic ossification (HO) in mice. Palovarotene (1 mg/kg/day ) is given orally for 14 days starting on a postoperative day (POD) 1 or POD-5, and HO amount wound dehiscence and related processes are monitored for up to 84 days post-injury. Compared to vehicle-control animals, Palovarotene significantly decreases HO by 50 to 60% regardless of when the treatment started and if the infection is present[1]. Starting from day 1 of injury, half of the Acvr1cR206H/+ mice are treated with Palovarotene by daily gavage for 14 days and the other half received a vehicle as control. Analysis by mCT and 3D image reconstruction at day 14 shows that large HO tissue masses have formed in the targeted leg of Acvr1cR206H/+ mutant mice receiving the vehicle, but HO formation is greatly diminished in Palovarotene-treated companions by more than 80% based on bone volume/total volume quantification[2]. |
别名 | Ro 3300074, R 667, 帕罗伐汀 |
分子量 | 414.54 |
分子式 | C27H30N2O2 |
CAS No. | 410528-02-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5.5 mg/mL (13.27 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4123 mL | 12.0616 mL | 24.1231 mL | 60.3078 mL |
5 mM | 0.4825 mL | 2.4123 mL | 4.8246 mL | 12.0616 mL | |
10 mM | 0.2412 mL | 1.2062 mL | 2.4123 mL | 6.0308 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
palovarotene 410528-02-8 Autophagy Metabolism Retinoid Receptor RAR/RXR inhibit Retinoid X receptors R667 Ro 3300074 R 667 Ro-3300074 Retinoic acid receptors Inhibitor R-667 帕罗伐汀 Ro3300074 inhibitor